表紙
市場調查報告書

生物標記分析的技術創新

Innovations in Biomarker Analytics

出版商 Frost & Sullivan 商品編碼 914934
出版日期 內容資訊 英文 49 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物標記分析的技術創新 Innovations in Biomarker Analytics
出版日期: 2019年10月14日內容資訊: 英文 49 Pages
簡介

這幾年,生物標記分析大幅發展,推動藥物開發過程的加速。AI為基礎技術的使用,也提高生物標記分析的效率。

本報告提供生物標記分析的技術創新趨勢的相關調查,市場趨勢與課題,產業聯合趨勢等相關彙整。

第1章 摘要整理

第2章 生物標記與分析:簡介

  • 藥物開發過程的生物標記和所扮演的角色
  • 生物標記特定貢獻的重要資料作成流程
  • 生物標記有在藥物開發過程中多樣的使用法

第3章 生物標記和大量資料

  • 資料處理與模式識別
  • 能考慮的資料來源
  • 影響因素
  • 重要方面和流程

第4章 影響生物標記分析上AI使用的促進要素與課題

  • 影響因素
  • 短期的,長期的影響

第5章 與對生物標記分析與藥物開發的AI的資金籌措投資

全世界的生命科學的投資擴大

第6章 各種產業聯合的時間軸

第7章 產業趨勢

  • 企業簡介:NuMedii和 Recursion Pharmaceuticals
  • 企業簡介:GNS Healthcare Insilico Medicine
  • 企業簡介:Standigm twoXAR
  • 企業簡介:ExScientia BioXcel Therapeutics
  • 企業簡介:Benevolent AI Berg Health

第8章 成長的機會

第9章 附錄

目錄
Product Code: D8DA

Tracking the Market Landscape of Companies Striving to Derive Actionable Insights from the Data Deluge through the incorporation of Artificial Intelligence

Biomarker Analytics has always been one of the most in-demand branches of science relevant to the process of drug discovery and development in the Pharmaceutical Industry. Over the years several advances have been made in the area of biomarker analytics with the aim to accelerate the drug development process. The use of AI-based technology can increase the efficiency of biomarker analytics.

With the huge data deluges generated through various platforms such as omics, diagnostics etc., machine learning and deep learning techniques are slowly proving to be highly effective in sifting through data and identifying critical biomarkers through pattern recognition. This global research service provides extensive information about the industry trends, market landscape, latest technological advances and AI-based developments in the biomarker analytics industry that hold immense potential in accelerating the process of drug development in the pharmaceutical industry.

Table of Contents

1.0 Executive Summary

  • 1.1 Research Objectives
  • 1.2 Research Methodology
  • 1.3 Key Predictions: Biomarker Analytics

2.0 Biomarkers and Analytics--Introduction

  • 2.1 Biomarkers and Their Role in Drug Development Process
  • 2.2 Critical Data Generation Processes Contributing to Biomarker Identification
  • 2.3 Biomarkers Have Multiple Uses in Drug Development Process

3.0 Biomarkers and Data Deluge

  • 3.1 Data Processing and Pattern Recognition Key to Biomarker Analytics
  • 3.2 Possible Data Sources for Biomarker Analytics
  • 3.3 Factors Affecting Use of AI in Biomarker Analytics
  • 3.4 Key Aspects and Processes for The Use of AI for Biomarker Analytics

4.0 Drivers and Challenges Affecting the Use of AI for Biomarker Analytics

  • 4.1 Factors Impacting The Use of AI for Biomarker Analytics
  • 4.2 AI Will Have Both Short-Term and Long-Term Effect on Biomarker Analytics

5.0 Funding and Investments in AI for Biomarker Analytics and Drug Development

  • 5.1 Increasing Global Life Science Investments in AI startups Focused on Drug Development
  • 5.2 Recursion Pharmaceuticals Has Pulled in The Highest Individual Series Funding Round for AI-Based Drug Discovery
  • 5.3 Benevolent AI Is Currently The Highest Funded AI-based Drug Discovery Venture

6.0 Timeline of Various Industrial Collaborations

  • 6.1 Numerate, NuMedii, and ExScientia Were Some of The Early Movers
  • 6.2 Benevolent AI and Insilico Medicine Were The Trailblazers
  • 6.3 Multiple Research Collaborations Were Agreed in 2016/2017
  • 6.4 GNS Healthcare Reported The Highest Number of Industrial Collaborations in 2017
  • 6.5 Year 2018 Marked The Entry of Multiple AI-based Startups Focused on Biomarker Analytics and Drug Discovery
  • 6.6 Industrial Collaborations Continue to Be A Global Phenomenon Rather Than Regional Ones
  • 6.7 Atomwise Reported The Highest Potential Industrial Collaboration Deal in 2019
  • 6.8 Global Trends Position North America and Europe as Leaders in Applying AI for Biomarkers and Drug Development Process

7.0 Industry Landscape of selected companies

  • 7.1 Company Profile: NuMedii & Recursion Pharmaceuticals
  • 7.2 Company Profile: GNS Healthcare & Insilico Medicine
  • 7.3 Company Profile: Standigm & twoXAR
  • 7.4 Company Profile: ExScientia & BioXcel Therapeutics
  • 7.5 Company Profile: Benevolent AI & Berg Health

8.0 Growth Opportunities

  • 8.1 Growth Opportunity 1: Adoption of AI by The Pharmaceutical Industry for Biomarker Analytics
  • 8Industrial Collaborations Can Lead to Increased Access to Proprietary Databases
  • 8Building More Effective Algorithms and Eliminating Data Bias

9.0 Appendix

  • 9.1 Key Contacts
  • 9.1 Key Contacts (continued)
  • 9.1 Key Contacts (continued)
  • Legal Disclaimer
Back to Top